HUTCHMED’s New Investigational Agent Shows Activity in Across 55 Tumor Cell Lines

HUTCHMED’s New Investigational Agent Shows Activity in Across 55 Tumor Cell Lines

HUTCHMED reported on November 19, 2026, that HMPL-A830, an investigational antibody conjugate designed to inhibit both EGFR and KRAS signaling, showed activity across tumor cell lines with several KRAS alterations and produced dose-dependent antitumor effects in mice. The findings were presented at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, held November 18-20 in Barcelona, Spain.

A global Phase I trial is evaluating the therapy in patients with advanced solid tumors.

Why HUTCHMED Is Targeting EGFR and KRAS Together

HMPL-A830 combines an antibody against epidermal growth factor receptor (EGFR) with a small-molecule KRAS inhibitor. The antibody is designed to bind to EGFR on the surface of tumor cells and deliver the inhibitor into those cells. The approach is intended to suppress signaling at two points in the same pathway.

One rationale for targeting both proteins is that EGFR can contribute to resistance to KRAS inhibition. In colorectal cancer, increased signaling through EGFR can reactivate the MAPK pathway during treatment, limiting the depth and duration of KRAS pathway suppression. HUTCHMED designed the conjugate to address that feedback while directing the KRAS inhibitor toward EGFR-expressing tumors. Systemic inhibition of the RAS pathway can also affect normal tissue, with dermatologic toxicity among the effects cited by the company.

Activity Across KRAS Alterations in Tumor Cell Lines

Laboratory profiling showed that the payload interfered with two processes in the KRAS activation cycle. It blocked the binding of active, GTP-bound KRAS to RAF1, a step in transmitting the downstream signal. It also inhibited the exchange of GDP for GTP, which switches KRAS from its inactive state into its active state.

HUTCHMED reported antiproliferative activity across a panel of 55 tumor cell lines harboring a range of KRAS alterations. The panel included G12C, G12D, G12V and G13D mutations, as well as amplification of wild-type KRAS. The company also described three findings related to the antibody component and the behavior of the conjugate in laboratory testing.

  • Binding and internalization: HMPL-A830 showed high binding affinity for EGFR and was rapidly taken up by EGFR-positive cells.
  • Bystander activity: The conjugate killed neighboring EGFR-negative tumor cells in laboratory testing, showing activity beyond cells that expressed the antibody’s target.
  • Antibody-dependent cellular cytotoxicity: The conjugate retained the ability to engage this immune-mediated mechanism of tumor cell killing.

Tumor Regression and Comparator Findings in Mice

In mouse models of EGFR-positive tumors with KRAS alterations, HUTCHMED observed dose-dependent antitumor activity. The company reported that tumor regressions lasted longer with HMPL-A830 than with KRAS G12C inhibitors. It also reported greater antitumor activity with HMPL-A830 than with the following comparators tested in mice.

  • The unconjugated EGFR antibody, which was administered without the KRAS inhibitor payload.
  • A pan-RAS inhibitor, tested both as a single agent and in combination with cetuximab.
  • A TROP2-directed antibody-drug conjugate carrying a topoisomerase I inhibitor payload.

Pharmacokinetic and pharmacodynamic analyses also showed stronger and more sustained inhibition of downstream EGFR and KRAS signaling with HMPL-A830 than with the unconjugated antibody. In plasma testing, the drug-to-antibody ratio, which describes the amount of payload attached to the antibody, remained stable in mouse, monkey and human plasma. The announcement did not include patient efficacy, safety or tolerability results.

Global Phase I Trial and GSK Licensing Agreement

The Phase Ia portion of the ongoing global Phase I trial is evaluating HMPL-A830 in patients with unresectable, advanced or metastatic solid tumors. HUTCHMED Limited is responsible for the global Phase I development program. The company did not specify when it expects to report results from the study.

For subsequent development, a GSK subsidiary holds exclusive rights to develop and commercialize HMPL-A830 worldwide outside Mainland China, Hong Kong, Macau and Taiwan under an agreement signed in September 2026. The GSK subsidiary will lead subsequent clinical development and commercialization in the territories covered by the license.

You can also read: HUTCHMED and GSK Sign Up to $1.295B Licensing Deal for KRAS-EGFR Cancer Therapy HMPL-A830.

HUTCHMED